Main

processing priority

4

site type

3 (personal blog or private political site, e.g. Blogspot, Substack, also small blogs on own domains)

review version

11

html import

20 (imported)

Events

first seen date

2025-01-08 23:46:11

expired found date

-

created at

2025-01-08 23:46:11

updated at

2025-07-31 02:42:34

Domain name statistics

length

23

crc

17162

tld

2211

nm parts

0

nm random digits

0

nm rare letters

0

Connections

is subdomain of id

69893241 (blogspot.com)

previous id

0

replaced with id

0

related id

-

dns primary id

0

dns alternative id

0

lifecycle status

0 (unclassified, or currently active)

Subdomains and pages

deleted subdomains

0

page imported products

0

page imported random

0

page imported parking

0

Error counters

count skipped due to recent timeouts on the same server IP

0

count content received but rejected due to 11-799

0

count dns errors

0

count cert errors

0

count timeouts

0

count http 429

0

count http 404

0

count http 403

0

count http 5xx

0

next operation date

-

Server

server bits

server ip

-

Mainpage statistics

mp import status

20

mp rejected date

-

mp saved date

-

mp size orig

305712

mp size raw text

55608

mp inner links count

0

mp inner links status

1 (no links)

Open Graph

title

Med-Chemist

description

image

site name

author

updated

2026-01-13 16:47:31

raw text

Med-Chemist Med-Chemist : "Quintessential Medicinal Chemistry" Tuesday, October 8, 2024 FDA Approves Tepylute (thiotepa) Ready-to-Dilute Injectable Formulation to Treat Breast Cancer and Ovarian Cancer Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s New Drug Application (NDA) for Tepylute, a ready-to-dilute formulation to treat breast and ovarian cancer in an easier to prepare, injectable product that enables dosing accuracy. Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s New Drug Application (NDA) for  Tepylute , a ready-to-dilute formulation to treat breast and ovarian cancer in an easier to prepare, injectable product that enables dosing accuracy. 1 ‘’This approval fulfills an unmet need by addressing the shortcomings and handling...

Text analysis

redirect type

0 (-)

block type

0 (no issues)

detected language

1 (English)

category id

Medicine [en] (226)

index version

2025123101

spam phrases

1

Text statistics

text nonlatin

0

text cyrillic

0

text characters

44903

text words

8089

text unique words

1878

text lines

456

text sentences

259

text paragraphs

103

text words per sentence

31

text matched phrases

58

text matched dictionaries

18

RSS

rss status

32 (unknown)

rss found date

2025-01-08 23:46:14

rss size orig

490728

rss items

25

rss spam phrases

10

rss detected language

1 (English)

inbefore feed id

-

inbefore status

0 (new)

Sitemap

sitemap status

40 (completed successful import of reports.txt file to table in_pages)

sitemap review version

2

sitemap urls count

2929

sitemap urls adult

0

sitemap filtered products

0

sitemap filtered videos

0

sitemap found date

2025-01-08 23:46:12

sitemap process date

2025-03-25 03:41:06

sitemap first import date

-

sitemap last import date

2025-07-31 02:42:34